[{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"5455e56f-c7d0-43e1-93b2-556c1632eeb2","acronym":"UCLA l-08","url":"https://clinicaltrials.gov/study/NCT04285671","created_at":"2023-11-26T01:10:15.098Z","updated_at":"2024-07-02T16:34:26.639Z","phase":"Phase 1/2","brief_title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04285671 - UCLA l-08","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HER-2 • AXL","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["HER-2 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 12/02/2025","primary_completion_date":" 12/02/2025","study_txt":" Completion: 12/02/2026","study_completion_date":" 12/02/2026","last_update_posted":"2024-06-13"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"22513496-b57b-422f-a9cc-b4cffc6c0a59","acronym":"ADCT-601-102","url":"https://clinicaltrials.gov/study/NCT05389462","created_at":"2022-05-25T13:55:41.985Z","updated_at":"2024-07-02T16:35:08.900Z","phase":"Phase 1","brief_title":"A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors","source_id_and_acronym":"NCT05389462 - ADCT-601-102","lead_sponsor":"ADC Therapeutics S.A.","biomarkers":" AXL","pipe":"","alterations":" ","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • mipasetamab uzoptirine (ADCT-601)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-18"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"9a153527-03e4-4f0e-a267-102de598735a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410717","created_at":"2022-06-08T11:58:15.716Z","updated_at":"2024-07-02T16:35:24.094Z","phase":"Phase 1","brief_title":"CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors","source_id_and_acronym":"NCT05410717","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" AXL • MSLN • CLDN6 • GPC3","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AXL • MSLN • CLDN6 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6-CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/31/2034","study_completion_date":" 05/31/2034","last_update_posted":"2024-01-09"},{"id":"a244e177-3024-4585-8143-53da436ade5d","acronym":"MK-3475 PN531","url":"https://clinicaltrials.gov/study/NCT03184571","created_at":"2021-01-17T17:21:07.066Z","updated_at":"2025-02-25T16:06:25.427Z","phase":"Phase 2","brief_title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03184571 - MK-3475 PN531","lead_sponsor":"BerGenBio ASA","biomarkers":" EGFR • PD-L1 • ALK • AXL","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bemcentinib (BGB324)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 10/17/2017","start_date":" 10/17/2017","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2023-10-09"},{"id":"101983fb-7628-475a-80b5-d17bf993dca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02988817","created_at":"2021-12-09T22:53:42.151Z","updated_at":"2024-07-02T16:35:41.314Z","phase":"Phase 1/2","brief_title":"Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02988817","lead_sponsor":"Genmab","biomarkers":" AXL • MUC16","pipe":" | ","alterations":" AXL expression • AXL positive","tags":["AXL • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression • AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enapotamab vedotin (HuMax-AXL-ADC)"],"overall_status":"Completed","enrollment":" Enrollment 306","initiation":"Initiation: 11/23/2016","start_date":" 11/23/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2023-08-01"},{"id":"6575bade-72bb-495f-8e06-eb39a449767d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639508","created_at":"2021-01-17T17:26:36.480Z","updated_at":"2024-07-02T16:35:44.723Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","source_id_and_acronym":"NCT01639508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" RET • ROS1 • KIF5B • AXL • NTRK","pipe":" | ","alterations":" RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion","tags":["RET • ROS1 • KIF5B • AXL • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-26"},{"id":"cde39ba4-f1a3-4ae2-88e4-185a75217b66","acronym":"NCI-2018-02990","url":"https://clinicaltrials.gov/study/NCT03769311","created_at":"2021-01-18T18:38:59.586Z","updated_at":"2024-07-02T16:35:47.258Z","phase":"Phase 2","brief_title":"Cetuximab in Head and Neck Cancer Patients","source_id_and_acronym":"NCT03769311 - NCI-2018-02990","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AXL","pipe":" | ","alterations":" AXL expression","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 03/15/2022","primary_completion_date":" 03/15/2022","study_txt":" Completion: 03/15/2022","study_completion_date":" 03/15/2022","last_update_posted":"2023-05-24"},{"id":"3fbb4956-9efb-48d1-85dd-3eccb081995e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05128786","created_at":"2021-11-22T14:53:25.733Z","updated_at":"2024-07-02T16:35:50.288Z","phase":"Phase 1","brief_title":"CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas","source_id_and_acronym":"NCT05128786","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" AXL","pipe":" | ","alterations":" AXL positive","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CCT301-038"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 08/15/2025","study_completion_date":" 08/15/2025","last_update_posted":"2023-04-18"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"869b7fc3-fa55-4cce-bd59-7c2b929a6506","acronym":"CTC-AXL-PANC","url":"https://clinicaltrials.gov/study/NCT05346536","created_at":"2022-04-26T13:53:44.073Z","updated_at":"2024-07-02T16:36:07.763Z","phase":"","brief_title":"Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)","source_id_and_acronym":"NCT05346536 - CTC-AXL-PANC","lead_sponsor":"University Hospital, Montpellier","biomarkers":" PD-L1 • AXL","pipe":"","alterations":" ","tags":["PD-L1 • AXL"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 06/16/2022","start_date":" 06/16/2022","primary_txt":" Primary completion: 06/16/2023","primary_completion_date":" 06/16/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2022-07-06"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"57590c99-52a7-47e1-b57d-87dc82ca1906","acronym":"","url":"https://clinicaltrials.gov/study/NCT03393936","created_at":"2021-01-18T16:44:54.019Z","updated_at":"2024-07-02T16:36:22.653Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma","source_id_and_acronym":"NCT03393936","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" AXL • ROR2","pipe":"","alterations":" ","tags":["AXL • ROR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CCT301-038 • CCT301-59"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-10-21"},{"id":"5952600c-1558-48e1-9ded-cd63c4250110","acronym":"LOLA","url":"https://clinicaltrials.gov/study/NCT04427787","created_at":"2021-03-16T19:52:54.538Z","updated_at":"2024-07-02T16:36:24.800Z","phase":"Phase 2","brief_title":"A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET","source_id_and_acronym":"NCT04427787 - LOLA","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" AXL • KDR • SSTR2","pipe":"","alterations":" ","tags":["AXL • KDR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2021-09-06"},{"id":"398ab36d-6350-4f34-a4fb-1d2fa0d5b182","acronym":"","url":"https://clinicaltrials.gov/study/NCT03536208","created_at":"2021-01-18T17:25:04.177Z","updated_at":"2024-07-02T16:36:32.822Z","phase":"Phase 1","brief_title":"Biological Effect of Warfarin on Pancreatic Cancer","source_id_and_acronym":"NCT03536208","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" AXL","pipe":"","alterations":" ","tags":["AXL"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-03-25"},{"id":"0550fb9c-b9bd-4921-9d69-c2e4ef4dcbf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00697632","created_at":"2021-01-18T02:36:31.892Z","updated_at":"2024-07-02T16:37:02.876Z","phase":"Phase 1","brief_title":"Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies","source_id_and_acronym":"NCT00697632","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MET • AXL","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • AXL expression","tags":["MET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • AXL expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e glesatinib (MGCD265)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-12"},{"id":"94428c94-502d-4697-bd0c-e65bcada5be5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01139333","created_at":"2021-01-18T04:31:48.635Z","updated_at":"2024-07-02T16:37:32.060Z","phase":"","brief_title":"Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01139333","lead_sponsor":"Children's Oncology Group","biomarkers":" AXL","pipe":"","alterations":" ","tags":["AXL"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-18"}]